> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # Parabilis Raised $670M to Drug the Target Oncology Couldn't Touch - URL: https://nexi.fund/parabilis-medicines-record-biotech-ipo-2026/ - Published: 2026-09-25T09:00:30.000Z - Updated: 2026-09-25T09:00:30.000Z - Description: Parabilis listed on Nasdaq in June with the largest US biotech IPO of 2026, then kept building: a first-in-class ฮฒ-catenin:TCF inhibitor, a $125M Regeneron partnership and $1.1B in cash. The 2027 Phase 3 desmoid readout will test the platform. - Author: Nexi.fund Labs - Tags: Biotech & Health, #mode-5, #hook-statistic, #track-E, #brand-heavy $670 million. That was the gross haul when Parabilis Medicines opened on Nasdaq on June 10 โ€” the largest US biotech IPO of 2026\. The underwriters had marketed the deal at $17 to $19 a share. The book priced at $20, and the offer grew from 25 million shares to 33.3 million. The first session closed 58% higher. By late August the stock traded 96% above its offer price, while much of the year's biotech cohort gave its gains back. A record listing, held by a company most investors had never heard of six months earlier. ๐ŸŽฏ The $670 million listing was the biggest US biotech IPO of 2026, and it funded a single clinical asset rather than a diversified pipeline. That asset, zolucatetide, directly inhibits ฮฒ-catenin:TCF โ€” a target oncology spent three decades failing to reach. Regeneron paid $125 million upfront for the same platform before the IPO priced, with up to $2.2 billion in milestones behind it. ## Fog Pharma, then everything else The company started in 2016 as Fog Pharmaceuticals, a Cambridge, Massachusetts lab built around one stubborn claim: the proteins inside a cell had been written off as undruggable because no conventional small molecule or antibody could reach them. Greg Verdine, a chemist who had already built and sold several protein-focused companies, founded it to prove otherwise. ``` TIMELINE: Fog Pharma to Parabilis โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€ 2016 โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€ 2025 โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€ 2026 โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€ 2026 โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€ 2027 ๐Ÿ”ฌ ๐Ÿงช ๐Ÿ”ฌ ๐Ÿญ ๐Ÿ”ฅ Fog founded Fast Track & Regeneron $670M IPO Phase 3 (Verdine) Orphan Drug AHC deal (record) desmoid โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€โ”€ Source: Parabilis Medicines investor relations, 2026 ``` Fog changed its name. It kept its thesis. ## What a Helicon actually is A Helicon is a stabilised alpha-helical peptide โ€” a short chain of amino acids locked into a spring shape that crosses the cell membrane and presses flat against an intracellular protein. Parabilis calls them intracellular antibodies. The analogy holds on the mechanism. An antibody binds its target outside the cell. A Helicon binds one inside it. Zolucatetide, the lead program, blocks the interaction between ฮฒ-catenin and T-cell factor (TCF), the molecular switch that keeps the Wnt signalling pathway running. Most sporadic desmoid tumours carry a mutation in the CTNNB1 gene that removes the brake on that switch, so cells keep dividing when they should stop. Three decades of drug programs failed to touch the interaction directly. Zolucatetide is the first to try. | Modality | Target location | Cell penetration | Reachable targets | | ------------------- | ----------------------- | ---------------- | ------------------------------- | | **Small molecule** | Inside cell | โœ” High | Pockets and enzymes | | **Antibody** | Cell surface / secreted | โœ— None | Receptors and ligands | | **Helicon peptide** | Inside cell | โ— Engineered | Flat protein-protein interfaces | Parabilis Medicines platform materials, 2026 $670M record biotech IPO #### Parabilis IPO gross proceeds The largest US biotech listing of 2026, priced at $20 a share under the ticker PBLS. ยท *Endpoints News, 2026* ## The deal that priced the platform Regeneron signed its collaboration on May 18 โ€” three weeks before the listing. The terms read like a valuation: $125 million upfront in cash and equity, up to $2.2 billion across development, regulatory and commercial milestones, and tiered royalties on anything that reaches the market. What Regeneron bought is an Antibody-Helicon Conjugate (AHC) โ€” an antibody that carries a Helicon payload to a chosen cell type, then releases a peptide that hits a protein inside that cell. The buyer had just absorbed setbacks in its own cancer portfolio. Its existing antibody stack could not reach those targets. Here, the limitation became the purchase. > Our Helicons are like intracellular antibodies. They cross the cell membrane and bind challenging protein surfaces that are out of reach for other classes of medicines.โ€” Parabilis Medicines, Helicon platform materials ## The cash and the clock The company ended the second quarter with $1.1 billion in cash, equivalents and marketable securities. Management says that funds operations into 2030\. The listing proceeds carry a specific map: $150 million for the desmoid trials, $120 million to widen zolucatetide into other indications, and $190 million to push earlier Helicon programs toward the clinic. The Phase 3 registrational trial in desmoid tumours is scheduled to begin in the first half of 2027\. One readout carries the platform. $1.1B cash and securities #### Reported runway after listing Funds operations into 2030, according to management guidance. ยท *Parabilis IR, August 2026* ## Where it could go wrong Desmoid tumours are rare. A clean Phase 3 win still lands in a small commercial pool, and the wider case leans on FAP and other Wnt-driven solid tumours that have not produced human data yet. One asset carries concentration risk that a portfolio company spreads across several bets. Competition in engineered peptide platforms is no longer thin. Bicycle Therapeutics is running its own clinical bicyclic peptide programs, and Generate Biomedicines listed in February with a $400 million IPO on machine-designed proteins. Both compete for the same investor thesis: that engineered peptides can reach what antibodies cannot. The listing window that made the IPO possible has narrowed since. BioBucks counted 21 US biotech IPOs in 2026, then logged a fourth straight week without a new pricing by late August. It rode the top of that wave. A company that lists at the peak inherits the downside of the cycle that follows. ## What the number really measures Strip the ticker away and the story turns on modality. Peptide therapeutics sat at the edge of oncology for years โ€” good in metabolism, hard to aim at intracellular targets. Helicons add cell penetration and a shape built to bind flat protein surfaces. Regeneron paid before retail money arrived, which is the cleaner signal. As [we wrote in September](https://nexi.fund/twostep-peptide-drug-conjugate-2026/), peptide chemistry is being rebuilt around delivery and stability. Zolucatetide is the first test of whether that work clears a Phase 3\. If it does, $670 million stops looking like a record and starts looking like a platform price. ## Sources [ Parabilis' $670M IPO sets new biotech record Endpoints News reports the record listing and what the proceeds will fund. Endpoints News ](https://endpoints.news/parabilis-670m-ipo-sets-new-biotech-record-will-fund-cancer-drug?ref=nexi.fund) Primary trade coverage of the June IPO and its pricing. [ Q2 2026 results and business update Company disclosure of the Regeneron terms, cash position and Phase 3 timeline. Parabilis Medicines IR ](https://www.globenewswire.com/de/news-release/2026/08/13/3344336/0/en/parabilis-medicines-reports-second-quarter-2026-financial-results-and-provides-business-updates.html?ref=nexi.fund) The primary-source update behind the numbers cited here. [ About Helicons: the platform behind zolucatetide Company explanation of how stabilised helical peptides reach intracellular targets. Parabilis Medicines ](https://parabilismed.com/innovation/about-helicons?ref=nexi.fund) Defines the modality at the centre of the investment case.